DailyIQ
DailyIQ
Last updatedUpdating…

BSX·Boston Scientific Corporation

$43.16
-1.48 (-3.32%)
High
$44.41
Open
$43.35
Market Cap
65.26B
52W High
$105.65
Low
$42.78
P. Close
$43.16
P/E
17.76
52W Low
$38.60
Fwd P/E
14.26
DailyIQ Est.
$50.89
Inst. Own.
75.2%
Short Interest
2.69%
Days to Cover
2.6
NewEarnings release, scored · filed Oct 28, 2026tone -13.5 vs prior release · 62 lines scoredSee the breakdown
Technical Score (1D)
3
BEARISH
News Sentiment
50
MIXED
On Nov 5, Boston Scientific Corporation (BSX) was reported as one of the most watched stocks on Zacks.com, indicating a surge in analyst and investor attention. The coverage highlighted that the company had attracted significant interest from users of the platform, reflecting growing market focus on the firm. No new earnings reports or product announcements were disclosed in the article. The piece emphasized that the heightened visibility stemmed from general market sentiment rather than concrete corporate developments. As a result, the coverage underscored increased visibility without providing new financial or operational data.
LOW TARGET
$41 -5.0%
2 analysts
MEAN TARGET
$50 +14.9%
19 analysts
HIGH TARGET
$60 +39.0%
17 analysts
PRICE RANGE
$41.00 - $60.00
SB / B / H / S / SS
8/16/12/1/1
DAILYIQ EST.
$50.89 (+17.9%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Symbol
BSX
Description
Boston Scientific Corporation is a global medical device manufacturer specializing in interventional medical specialties. The company's core business involves developing, manufacturing, and marketing a diverse portfolio of devices used in the MedSurg and Cardiovascular segments. These offerings span a wide range of applications, including gastrointestinal, urological, and neurological treatments, as well as devices for managing chronic pain. Boston Scientific also provides critical technologies for diagnosing and treating cardiovascular diseases, including coronary artery disease and aortic valve conditions, along with devices for heart rhythm management and peripheral arterial disease. Incorporated in 1979, the company is headquartered in Marlborough, Massachusetts.
Bought (1Y)
206,362 shares
$10.0M
Sold (1Y)
3,449 shares
$150K
O'Sullivan MiriamSVP, Chief HR Officer
Option Exercise3,871 shares2026-11-01
O'Sullivan MiriamSVP, Chief HR Officer
Tax Withholding1,872 shares2026-11-01
O'Sullivan MiriamSVP, Chief HR Officer
Option Exercise3,871 shares2026-11-01
O'Connor Padraig AndrewEVP, Global Operations
Option Exercise1,171 shares2026-09-02
O'Connor Padraig AndrewEVP, Global Operations
Tax Withholding567 shares2026-09-02
82/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
69.0%
Net Margin
14.4%
Revenue CAGR
5.0%
Current Ratio
1.62x
Debt / Equity
0.47x
Return on Equity
11.9%
Earnings Summary
In Q3 2026, the company reported revenue of $5.138 billion and EPS of $0.73, slightly below the $0.73 estimate, while Q4 2026 results are pending; Q2 2026 revenue rose to $5.442 billion, up 5.0 % YoY, with EPS of $0.86 beating the $0.83 estimate. Compared to Q1–Q2 2026, revenue growth remained positive but slowed, and EPS growth moderated, with Q1 2026 EPS at $0.80 matching the $0.80 estimate and Q2 2026 EPS at $0.86 exceeding the $0.83 estimate. Historically, Boston Scientific has maintained consistent revenue growth, with EPS generally meeting or surpassing analyst forecasts over the past four quarters, though Q3 2026 EPS fell short of the $0.80 estimate, reflecting the impact of a cyberattack that disrupted manufacturing and shipments. The company’s pattern shows resilient top‑line performance but occasional earnings dips tied to operational disruptions. Recent news includes multiple analyst downgrades and price target cuts following a cyberattack that caused an 8‑day production halt, impairment charges, and a lowered full‑year outlook; however, the firm also secured FDA clearances for new urology and lithotripsy devices and announced an AI‑powered procedural planning partnership, bolstering its product pipeline. The key will be how effectively Boston Scientific mitigates operational risks while sustaining its competitive edge in high‑growth device segments.

EPS

EstBeatMiss
$0.69$0.74$0.79$0.83$0.88Q3'25Q4'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$0.78 - -
Q3'26$0.72$0.73+0.9%
Q2'26$0.83$0.86+3.9%
Q1'26$0.79$0.80+1.6%
Q4'25$0.79$0.80+1.6%
Q3'25$0.71$0.75+5.1%

Revenue

EstBeatMiss
$5.0B$5.1B$5.3B$5.4B$5.5BQ3'25Q4'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$5.2B - -
Q3'26$5.1B$5.1B+0.8%
Q2'26$5.4B$5.4B+0.5%
Q1'26$5.2B$5.2B+0.6%
Q4'25$5.3B$5.3B-0.9%
Q3'25 - $5.1B -

Market Data

BSX Stock Snapshot

BEARISH3/100
$43.16−$1.48 (3.3%)
Market cap
65.26B
P/E ratio
17.8
Day range
$42.78 – $44.41
News sentiment
50/100 · Neutral
Analyst target
$49.60 (+14.9%)
Consensus
Buy · 38 analysts
52-week range+11.8% off low · -59.1% from high
$38.60$105.65
Price $43.16 DailyIQ Est. $50.89

BSX is on the weaker side of its setup, with little confirmation for a reversal yet. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into BSX?

CHEAP

At today's price, Boston Scientific Corporation needs to grow free cash flow about 5.1% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 7.31% cost of capital. Over the last five years its revenue has trended at 14.2% a year, so the market is asking for 9.1 percentage points below its own delivered rate. On that basis BSX looks priced below what its own growth record supports.

Implied FCF growth
5.1%
Growth trend
14.2%
Growth gap
-9.1 pts
Verdict
CHEAP
Discount rate (WACC)
7.31%
Beta
0.77

Behaviour On Record

What BSX's own history says about today's numbers

Realized volatility (21d)
42.3% 93rd pct
Below its peak
-57.6%
vs 200-day average
-17.6%
Up days (1y)
46%

Boston Scientific Corporation is currently running 42.3% annualised volatility over the last 21 sessions. Measured against BSX's own 13 years of daily returns rather than a market-wide average, that is the 93rd percentile — an extreme by its own standards, against a typical reading of 23.4%.

BSX is trading -57.6% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -17.7%, and the deepest was -57.7% in 2026. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits -17.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 7th percentile — a narrower gap than it typically runs. Over the past year BSX closed higher on 46% of sessions, and it is currently 2 sessions into a rising streak.

On November specifically: over 13 years of records, BSX finished the month higher 6 of 13 times, with a median return of -2.8% and an average of -0.2%. Its strongest month historically has been January at +5.5% on average, its weakest September at -2.3%.

Overnight risk is measurable too: BSX has opened more than 2% away from the prior close in 123 of 3,268 sessions (3.8% of the time), with the largest gaps running +9.8% and -9.7%.

Across the last 4 dated reports on file, BSX moved an average of 1.3% in the session after earnings, closing higher 3 of those 4 times, with a median move of +1.2% and a largest of +2.1%.

All figures computed from 3,269 daily closes between 2013-11-06 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against BSX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BSX's sector?

Boston Scientific Corporation sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Medical Devices industry group, BSX ranks 1st of 15 tracked industries, leading.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#1 of 15

Options Market

What is the options market pricing for BSX?

CallsPuts

For Boston Scientific Corporation's nearest expiry (2026-11-06, 0 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.01), with at-the-money implied volatility around 12.1%.

Put/call ratio (2026-11-06)
1.01
ATM implied volatility
12.1%
Total open interest
14,760

Analyst Consensus Estimates

What do analysts expect BSX to earn?

Analysts expect Boston Scientific Corporation to earn $3.18 per share in the fiscal year ending Dec 2026 and $3.49 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$0.78$0.77 to $0.7924$5.18B24
Mar 2027$0.74$0.70 to $0.7817$5.06B16
Jun 2027$19.62$0.77 to $76.004--
Sep 2027$0.80$0.76 to $0.864~$5.34B-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$3.18$3.15 to $3.2928$20.97B28
Dec 2027$3.15$3.02 to $3.6229$21.03B29
Dec 2028$3.30$3.24 to $3.416~$22.03B-
Dec 2029$3.49$3.40 to $3.582~$23.30B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on BSX?

TD Cowen most recently downgraded Boston Scientific Corporation to Hold on Oct 30, 2026 with a price target of $46 (from $56). Over the last 90 days, coverage has run 0 upgrades against 3 downgrades, a net bearish lean.

Latest action
TD Cowen: Hold
90-day upgrades
0
90-day downgrades
3
Net rating momentum
-3
DateFirmActionRatingPrice target
Oct 30, 2026TD CowenDowngradeBuy → Hold$56 → $46
Oct 30, 2026BarclaysMaintainedEqual-Weight$48 → $45
Oct 29, 2026JefferiesDowngradeBuy → Hold$60 → $46
Oct 29, 2026Canaccord GenuityMaintainedBuy$66 → $48
Oct 29, 2026BernsteinMaintainedOutperform$54 → $49
Oct 29, 2026RBC CapitalMaintainedOutperform$70 → $52
Oct 29, 2026CitigroupMaintainedNeutral$48 → $44
Oct 29, 2026Leerink PartnersMaintainedOutperform$55 → $50
Oct 29, 2026UBSMaintainedBuy$67 → $57
Oct 29, 2026Wells FargoMaintainedEqual-Weight$48 → $45
Oct 29, 2026BairdMaintainedOutperform$50 → $51
Oct 29, 2026BTIGMaintainedBuy$56 → $49

Earnings Release, Scored

What did Boston Scientific Corporation's latest earnings release say?

Filed Oct 28, 2026 · SEC Form 8-K, Exhibit 99

Tone57.4/ 100-13.5 vs prior release
Hedging words2.13per 100 words+1.34 vs prior release
Tone, last 3 releasesScale 50–76

Most important lines

  1. 1

    Received U.S. FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat patients with severely calcified peripheral artery disease both above and below the knee.

    New this quarter
  2. 2

    Received U.S. Food and Drug Administration (FDA) 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem, including the Navigator™ Flex Ureteral Access Sheath Set , designed to enable the use of suction to remove kidney stone debris, and the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with temperature sensing , designed to display real-time fluid temperature alongside ureteroscopy video for procedural monitoring.

    New this quarter
  3. 3

    As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.

    New this quarter

Peers & ETF holders

BSX peers & ETF holders

News & sentiment

What is the news saying about BSX?

BSX rose 2.3% over the month to Nov 6. News tone held between 3 and 67 from Oct 6 to Oct 13, then jumped to 51 on Oct 14.

Daily close and news tone, Oct 6 to Nov 6
$42$44$46Oct 6: tone 67Oct 7: tone 58Oct 8: tone 46Oct 9: tone 46Oct 12: tone 42Oct 13: tone 3Oct 14: tone 51Oct 15: tone 68Oct 16: tone 50Oct 19Oct 20: tone 29Oct 21: tone 64Oct 22: tone 59Oct 23: tone 81Oct 26: tone 44Oct 27: tone 42Oct 28: tone 31Oct 29: tone 35Oct 30: tone 25Nov 2: tone 61Nov 3: tone 43Nov 4: tone 73Nov 5: tone 50Nov 6Oct 6News toneNov 6123
  1. Oct 28 -6.4%same day: Boston Scientific announces results for third quarter 2026
  2. Nov 2 +5.5%same day: Boston Scientific Consensus Price Target Lowered by 10.06% to $57.12
  3. Nov 4 +5.3%same day: Boston Scientific (BSX) Secures $455 Million For A Next Generation Heart Pump

Technical analysis

How strong is BSX's momentum right now?

On the daily chart BSX ranks at the 3rd percentile for momentum against 1,060 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling BSX?

101 of the 243 tracked managers added to BSX in their latest 13F and 139 trimmed. Together they own 75.2% of the company, worth $48.9B. BlackRock and Vanguard Capital Management alone hold 15.0%.

101adding139trimming3unchanged
Largest holders by stake, latest 13FBar = share of BSX
  1. $5.5B positionTrimmed 1.6% last quarter
  2. $4.1B positionAdded 0.7% last quarter
  3. $3.0B positionAdded 3.1% last quarter
  4. $2.2B positionAdded 55.3% last quarter
  5. $2.0B positionTrimmed 38.4% last quarter
  6. $1.4B positionAdded 0.5% last quarter
  7. $1.3B positionTrimmed 0.0% last quarter
  8. $1.1B positionAdded 4.7% last quarter
  9. $1.5B positionAdded 126.1% last quarter
  10. $1.0B positionTrimmed 28.3% last quarter
Full holdings history

Congressional trading

Is Congress trading BSX?

6 members of Congress disclosed 25 BSX trades between Jul 31, 2025 and Sep 9, 2026: 11 buys and 14 sells, about $383.0K in estimated value.

BuysSellsJulOctJan ’26AprJul
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart

Discover more

How has BSX done against its peers?

Over the six months to Nov 6, BSX returned −22.9%. Of the 15 related stocks and ETFs, all did better, led by BDX at +44.6%.

Change since May 6, through Nov 6
−40%−20%0%+20%+40%+60%May 6JunJulAugSepOctNov 6BDX +44.6%BSX −22.9%